Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 21, 2020 - Issue 1-2
Submit an article Journal homepage
20,433
Views
112
CrossRef citations to date
0
Altmetric
Clinical Trials

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

Jesus S. Mora1 ALS Unit, Hospital San Rafael, Madrid, Spain; Correspondence[email protected]
View further author information
,
Angela Genge2 Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada; View further author information
,
Adriano Chio3 Department of Neuroscience, University of Turin, Turin, Italy; ORCID Iconhttps://orcid.org/0000-0001-9579-5341View further author information
ORCID Icon,
Conrado J. Estol4 Neurological Center for Treatment and Rehabilitation, Buenos Aires, Argentina;View further author information
,
Delia Chaverri5 Department of Neurology, ALS Unit, Hospital Carlos III, Madrid, Spain; View further author information
,
Maria Hernández5 Department of Neurology, ALS Unit, Hospital Carlos III, Madrid, Spain; View further author information
,
Saúl Marín5 Department of Neurology, ALS Unit, Hospital Carlos III, Madrid, Spain; View further author information
,
Javier Mascias5 Department of Neurology, ALS Unit, Hospital Carlos III, Madrid, Spain; View further author information
,
Gabriel E. Rodriguez6 Neurology Department, Neuron Motor Disease Clinic, Hospital JM Ramos, Buenos Aires, Argentina; View further author information
,
Monica Povedano7 Neurology Department, Bellvitge Hospital-IDIBELL, Barcelona, Spain; View further author information
,
Andrés Paipa7 Neurology Department, Bellvitge Hospital-IDIBELL, Barcelona, Spain; View further author information
,
Raul Dominguez7 Neurology Department, Bellvitge Hospital-IDIBELL, Barcelona, Spain; View further author information
,
Josep Gamez8 Neurology Department, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain; ORCID Iconhttps://orcid.org/0000-0003-3127-7486View further author information
ORCID Icon,
Maria Salvado8 Neurology Department, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain; View further author information
,
Christian Lunetta9 NEMO Clinical Centre, Serena Onlus Foundation, Milan, Italy; View further author information
,
Carlos Ballario10 Neurorosario, Rosario, Argentina; View further author information
,
Nilo Riva11 Department of Neurology-INSPE, San Raffaele Scientific Institute, Milan, Italy; View further author information
,
Jessica Mandrioli12 Department of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero Universitaria di Modena, Modena, Italy; View further author information
,
Alain Moussy13 AB Science, Paris, France; View further author information
,
Jean-Pierre Kinet13 AB Science, Paris, France; ;14 Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA; View further author information
,
Christian Auclair13 AB Science, Paris, France; ;15 Department of Biology, Université Paris Sud Université Paris-Saclay CNRS UMR 8113, Ecole Normale Supérieure de Cachan, Cachan, France; View further author information
,
Patrice Dubreuil13 AB Science, Paris, France; ;16 INSERM, CNRS, Institut Paoli-Calmettes, CRCM, Centre de Référence des Mastocytoses, Equipe Labelisée Ligue Nationale Contre le Cancer, Aix-Marseille University, Marseille, France; and View further author information
,
Vincent Arnold13 AB Science, Paris, France; View further author information
,
Colin D. Mansfield13 AB Science, Paris, France; View further author information
,
Olivier Hermine13 AB Science, Paris, France; ;17 Imagine Institute, INSERM UMR 1163 and CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms of Hemathological Disorders and Therapeutic Implication, Hôpital Necker, Paris, FranceView further author information
& on behalf of the AB10015 STUDY GROUP show all
Pages 5-14 | Received 23 Dec 2018, Accepted 04 Jun 2019, Published online: 07 Jul 2019

Related Research Data

El Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosis
Source: Informa UK Limited
Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression.
Source: American Medical Association (AMA)
Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient
Source: Baishideng Publishing Group Inc.
Edaravone: a new treatment for ALS on the horizon?
Source: Elsevier BV
The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials
Source: HAL CCSD
Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
Source: Ovid Technologies (Wolters Kluwer Health)
Projected increase in amyotrophic lateral sclerosis from 2015 to 2040.
Source: Springer Science and Business Media LLC
El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
Source: Elsevier BV
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study
Source: HAL CCSD
Comprehensive analysis of kinase inhibitor selectivity.
Source: Springer Science and Business Media LLC
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
Source: HAL CCSD

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.